IRICoR is pleased to announce the appointment of three new Directors to its Board.

IRICoR is pleased to announce the appointment of three new Directors to its Board: Ms. Annie Gauthier – lawyer and partner at the law firm BCF, Bettina Hamelin – President and CEO of Ontario Genomics and Mr. Bernard Lachapelle – President of The JBL Group Inc.

Annie Gauthier

Bettina Hamelin

Bernard Lachapelle

 

 

 

 

 

 

 

 

 

 

 

 

These three new Directors bring a range of expertise complementary to that already in place on the Board. They will enrich the business discussions on issues relating to business law, licensing, mergers and acquisitions, health policy and market access, novel academic-private partnership models and key governmental issues.

Mr. Jean-François Leprince, Chairman of the Board asserts: “I am happy to be able to rely on such a roster of experienced individuals on the Board. The arrival of these new Directors underscores the desire to position IRICoR as a value-creation cluster for state-of-the-art academic research geared towards commercializing highly innovative drugs. Our Board members are all experts in their respective fields and represent a strategic asset for the organization. Welcome to our new Directors! “.